Farmas USA

THLD, sera la buena ?

AMRN

Framus, sin duda bajar tu precio de compra sabiendo el lateral que se viene marcando y el cual tienes controlado (con sus pequeños detalles como no puede ser de otra manera) te permitirá sacarle mucho más, y ahí estamos todos.

OCAT

si no fuera por esa puñetera vela ... pero oye! romper ha roto!

Triskis, HZNP SEMANAL

Me gusta MUCHOOO!! 

Aunque no tengo ni idea del timing de las cosas con el culebron que se traen con DEPOMED

Pero ese martillo invertido tras una tendencia bajista y el martillo que llevamos en esta me esta gustando de verdad.

OCAT

Sí, romper ha roto, pero con muy poca fuerza. Volumen muy escaso estos días, así que un día tonto y se nos mete debajo de la bajista otra vez con 4 acciones. Eso sí, ayer parece que se apoyó en la bajista sin dar sustos y eso también es buena señal.

mi primera resistencia que veo es la zona de 5$.

si, tienes razon, los 5 son el primer escollo ...

OCAT

HZNP

Su oferta por DEPO caduca el 20 de nov y el 13 es junta extraordinaria de accionistas para abordar de nuevo el tema.

DUBLIN, IRELAND -- (Marketwired) -- 10/26/15 -- Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma"), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs today announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Depomed, Inc. ("Depomed") to 5 p.m., Eastern time, on November 20, 2015. An extraordinary general meeting of Horizon Pharma's shareholders is scheduled for November 13, 2015, the principal purpose of which is to approve the issuance of Horizon ordinary shares in connection with Horizon Pharma's proposed acquisition of Depomed. Horizon shareholder approval is one of the conditions required to consummate the exchange offer and the exchange offer is being extended until after the Horizon special meeting.

mugi, calentito, acabado de sacar del horno. Creo que de cash tenemos para unos cuantos trimestres y no es mucho lo que hemos aumentado el cash burn.
---
The Company had $220.7 million in cash, cash equivalents and marketable securities as of September 30, 2015, compared to $93.4 million at June 30, 2015. The balance at September 30, 2015 includes approximately $164 million of net proceeds from sales of common stock in the third quarter and reflects payment of all principal and accrued interest, prepayment charges and other fees totaling approximately $11 million under a loan agreement.

Operating expenses of $29.6 million for the quarter ended September 30, 2015 increased by $4.8 million compared to the quarter ended June 30, 2015 primarily due to production, clinical trial and commercial preparation costs.

We recently initiated a clinical trial to evaluate the combination of our cancer immunotherapeutic product candidate SD-101 and Merck's KEYTRUDA® (pembrolizumab) in patients with metastatic melanoma. All study visits for HBV-23, the Phase 3 clinical study of HEPLISAV-B™, were completed in October 2015. Top line results of this study are expected to be released in early 2016.

The net loss allocable to common stockholders for the quarter ended September 30, 2015 was $30.1 million, or $0.82 per basic and diluted share. The net loss allocable to common stockholders for the quarter ended June 30, 2015 was $23.6 million, or $0.80 per basic and diluted share.

http://investors.dynavax.com/releaseDetail.cfm?ReleaseID=940815
DVAX